PDL BioPharma, Inc. PDLI

Other  —  Other
Market cap
—
P/E
0.0×
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
P/E ratio
5.72 3.99 0.00 0.00 —
P/S ratio
1.50 1.39 2.13 7.04 —
P/FCF ratio
3.18 3.04 5.80 5.49 —
P/Operating CF
23.34 (25.57) (204.47) (20.14) —
P/B ratio
0.48 0.53 0.58 0.65 —
Price to Tangible BV
2.93 1.59 1.40 0.66 —
EV/Sales
1.46 0.10 0.77 4.45 —
EV/EBITDA
2.35 0.13 0.00 0.00 —
EV/Operating CF
3.50 0.77 (11.36) (7.52) —
EV/FCF
3.10 0.21 2.09 3.47 —
Quick Ratio
2.17 2.92 7.93 4.53 —
Current Ratio
3.05 3.32 9.86 6.87 —
Net Debt/EBITDA
(0.06) (1.79) 11.51 2.02 —
Debt/Assets
19.13% 9.45% 12.93% 3.81% 0.00%
Debt/Equity
0.31 0.14 0.17 0.05 —
Asset Turnover
0.22 0.26 0.18 0.07 0.00
Operating CF/Net income
1.60 0.37 0.20 0.46 —
Capex/Depreciation
0.59 2.78 1.97 4.70 —
Interest Coverage
0.00 0.00 0.00 0.00 —
ROE
8.76% 13.83% (8.74%) (10.64%) —
ROA
5.71% 9.01% (6.24%) (8.38%) 0.00%
ROIC
10.85% 28.09% (6.88%) (14.61%) —
Return on Tangible Assets
23.76% 24.36% (14.58%) (25.72%) —
Average Days of Receivables
59.94 35.56 39.88 90.34 —
Research and Development Expense of Revenue
1.56% 2.31% 1.49% 13.35% —
Selling, General and Administrative Expense of Revenue
16.51% 19.79% 31.58% 98.76% —
Intangible Assets out of Total Assets
0.52 0.45 0.44 0.40 0.00
Share Based Compensation of Revenue
1.53% 0.98% 2.40% 13.00% —
Graham Net Nets
(0.17) 0.55 0.67 0.49 —
Graham Number
6.36 9.39 0.00 0.00 —
Earnings Yield
17.49% 25.09% (15.52%) (19.38%) —
Free Cash Flow Yield
31.42% 32.87% 17.25% 18.23% —
Revenue per Share
1.49 2.06 1.36 0.46 —
Operating CF per Share
0.62 0.26 (0.09) (0.27) —
Capex per Share
0.08 0.68 0.37 0.69 —
Free Cash Flow per Share
0.70 0.94 0.27 0.42 —
Cash per Share
1.48 3.42 2.71 1.63 —
Shareholders Equity per Share
4.61 5.44 5.01 5.00 —
Interest Debt per Share
0.00 0.00 0.00 0.00 —
Book value per Share
4.61 5.44 5.01 5.00 —
Free Cash Flow
114.78 146.58 40.02 49.37 —
Working Capital
267.72 447.33 464.75 268.20 —
Capital Expenditures
13.06 105.96 53.45 81.81 —
Net Current Asset Value
(61.93) 243.21 283.26 191.05 —
EV/EBIT
2.75 0.16 0.00 0.00 —
Capex to Sales
(0.05) (0.33) (0.27) (1.49) —
Net Profit Margin
26.04% 34.60% (34.76%) (128.59%) —
Price to Operating Income
2.82 2.30 0.00 0.00 —
Other line items
Depreciation/Fixed assets
580.39 5.27 3.67 3.15 —
Cash ROIC
8.27% 2.23% (1.67%) (4.66%) —
Accounts Receivable Turnover
12.09 8.98 7.50 3.11 —
Accounts Payable Turnover
1.10 2.28 2.94 3.51 —
Inventory Turnover
0.68 5.08 3.45 1.83 —
Average Days of Payables
629.97 236.48 98.99 118.24 —
Days of Inventory on Hand
258.96 109.33 142.67 270.75 —
Average Receivables
20.21 35.65 26.42 17.60 —
Average Payables
3.71 13.40 16.46 15.26 —
Average Inventory
6.02 6.02 14.04 29.36 —
Average Assets
1,113.80 1,229.26 1,103.43 839.93 358.06
Average Common Equity
725.69 800.66 787.83 661.53 —

Fold the line items

Columns are period end dates